Hemgenix maintained factor IX levels at 37.4 IU/dL in year four, with a 90% reduction in annualized bleeding rates compared to baseline. At year four, 94% of patients remained off continuous ...
Investing.com -- Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B study, confirming the long-term efficacy and safety of ...
Chiron Behring, GlaxoSmithKline, Novartis, Roche, and/or Salix Pharmaceuticals. Dr. Nothdurft has been reimbursed by several manufacturers of vaccines and antimalarial prophylaxis for attending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback